Heat Biologics Inc (NASDAQ:HTBX)’s share price dropped 11.9% during mid-day trading on Thursday . The company traded as low as $0.72 and last traded at $0.74. Approximately 1,107,625 shares changed hands during mid-day trading, an increase of 118% from the average daily volume of 507,289 shares. The stock had previously closed at $0.84.

HTBX has been the topic of a number of recent research reports. ValuEngine cut Heat Biologics from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st. Alliance Global Partners set a $6.00 target price on Heat Biologics and gave the stock a “buy” rating in a report on Friday, May 17th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $7.67.

The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.70 and a current ratio of 5.70.

Hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC purchased a new position in shares of Heat Biologics during the first quarter valued at $62,000. Virtu Financial LLC purchased a new position in shares of Heat Biologics during the fourth quarter valued at $55,000. Northern Trust Corp grew its holdings in shares of Heat Biologics by 36.2% during the first quarter. Northern Trust Corp now owns 66,728 shares of the biopharmaceutical company’s stock valued at $85,000 after buying an additional 17,745 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Heat Biologics by 20.6% during the third quarter. Vanguard Group Inc. now owns 798,561 shares of the biopharmaceutical company’s stock valued at $1,597,000 after buying an additional 136,256 shares in the last quarter. Finally, Vanguard Group Inc grew its holdings in shares of Heat Biologics by 20.6% during the third quarter. Vanguard Group Inc now owns 798,561 shares of the biopharmaceutical company’s stock valued at $1,597,000 after buying an additional 136,256 shares in the last quarter. Institutional investors and hedge funds own 12.03% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://theolympiareport.com/2019/05/23/heat-biologics-htbx-stock-price-down-11-9.html.

About Heat Biologics (NASDAQ:HTBX)

Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.

Featured Story: How to Profit and Limit Losses With Stop Orders

Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.